Head to Head Contrast: PTC Therapeutics (PTCT) & Prothena Corporation PLC (PRTA)
PTC Therapeutics (NASDAQ: PTCT) and Prothena Corporation PLC (NASDAQ:PRTA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Institutional & Insider Ownership
81.3% of PTC Therapeutics shares are owned by institutional investors. 8.1% of PTC Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Prothena Corporation PLC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
PTC Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Prothena Corporation PLC has a beta of 2.6, meaning that its share price is 160% more volatile than the S&P 500.
This table compares PTC Therapeutics and Prothena Corporation PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Prothena Corporation PLC||-527.56%||-33.20%||-27.66%|
This is a summary of recent ratings for PTC Therapeutics and Prothena Corporation PLC, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Prothena Corporation PLC||0||0||12||0||3.00|
PTC Therapeutics presently has a consensus target price of $16.89, suggesting a potential downside of 9.30%. Prothena Corporation PLC has a consensus target price of $79.73, suggesting a potential upside of 25.04%. Given Prothena Corporation PLC’s stronger consensus rating and higher probable upside, analysts plainly believe Prothena Corporation PLC is more favorable than PTC Therapeutics.
Valuation & Earnings
This table compares PTC Therapeutics and Prothena Corporation PLC’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|PTC Therapeutics||$122.69 million||6.27||-$90.43 million||($3.10)||-6.01|
|Prothena Corporation PLC||$27.53 million||88.65||-$135.60 million||($4.12)||-15.48|
PTC Therapeutics has higher revenue and earnings than Prothena Corporation PLC. Prothena Corporation PLC is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Prothena Corporation PLC beats PTC Therapeutics on 7 of the 13 factors compared between the two stocks.
About PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.